AstriVax, a pioneering company in the field of vaccinology, has successfully initiated the clinical phase for its innovative vaccine platform technology. The commencement of the SAFYR clinical trial marks a significant milestone for the company, as it aims to assess the safety and efficacy of its prophylactic vaccines designed for yellow fever and rabies.
The clinical trial represents a critical step towards advancing AstriVax’s immunotherapies for chronic Hepatitis B and HPV infections. With the potential to revolutionize the fight against viral pathogens, the company’s novel vaccine platform is set to address crucial unmet medical needs, including the treatment of chronic Hepatitis B, which affects over 250 million people, and HPV infections, a leading cause of cervical cancer.
The SAFYR study will provide valuable insights into the safety and immune response of the company’s prophylactic vaccines, with the potential to demonstrate the clinical proof of concept for the innovative AstriVax vaccine platform. With strong support from investors and a talented team, AstriVax is poised to continue its journey towards better global health.
For more information, please visit astrivax.com.
Contact:
Hanne Callewaert, Ph.D.
CEO of AstriVax
[email protected].
About AstriVax:
AstriVax NV, established in 2022, is dedicated to addressing global challenges in vaccinology through its cutting-edge vaccine platform. The company focuses on developing novel prophylactic and therapeutic vaccines that offer broad and long-lasting protection against infectious diseases. Supported by renowned investors and located in the BioHub in Leuven, AstriVax is committed to driving innovation in the field of vaccinology.